CapsoVision (NASDAQ:CV) Major Shareholder Acquires $101,797.50 in Stock

CapsoVision, Inc. (NASDAQ:CV) major shareholder Eliyahou Et Al Harari acquired 13,850 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The shares were acquired at an average cost of $7.35 per share, for a total transaction of $101,797.50. Following the completion of the transaction, the insider directly owned 3,200,751 shares of the company’s stock, valued at $23,525,519.85. The trade was a 0.43% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

CapsoVision Stock Performance

Shares of NASDAQ:CV opened at $5.67 on Wednesday. The firm has a market cap of $283.27 million and a price-to-earnings ratio of -2.42. The business has a 50-day simple moving average of $6.90 and a two-hundred day simple moving average of $6.79. CapsoVision, Inc. has a fifty-two week low of $3.43 and a fifty-two week high of $15.37.

CapsoVision (NASDAQ:CV) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.15) EPS for the quarter. The firm had revenue of $2.79 million for the quarter.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG bought a new stake in shares of CapsoVision during the 4th quarter valued at $47,000. Wells Fargo & Company MN lifted its position in CapsoVision by 66.4% during the fourth quarter. Wells Fargo & Company MN now owns 6,287 shares of the company’s stock valued at $67,000 after purchasing an additional 2,508 shares in the last quarter. Citadel Advisors LLC bought a new stake in CapsoVision during the third quarter valued at about $115,000. Virtu Financial LLC bought a new position in shares of CapsoVision during the 4th quarter valued at approximately $128,000. Finally, Bank of America Corp DE increased its stake in shares of CapsoVision by 528.9% in the first quarter. Bank of America Corp DE now owns 22,238 shares of the company’s stock worth $162,000 after purchasing an additional 18,702 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Benchmark decreased their target price on shares of CapsoVision from $14.00 to $10.00 and set a “speculative buy” rating for the company in a research note on Friday, March 27th. Weiss Ratings restated a “sell (d-)” rating on shares of CapsoVision in a research note on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $8.50.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.